In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not require biomarker testing.
Brian Slomovitz, MD
Advertisement
Brian Slomovitz, MD, is director of gynecologic oncology and co-chair of the clinical research committee at Mount Sinai Medical Center in Miami Beach, Florida. He also serves as the clinical trial lead for uterine cancer for GOG Partners.
Articles by Brian Slomovitz, MD
Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global scope.
Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, according to Brian Slomovitz, MD, one of the investigators.
New findings reveal that relacorilant enhances survival rates in platinum-resistant ovarian cancer when combined with nab-paclitaxel, outperforming standard treatment.
Advertisement
Latest Updated Articles
SPOTLIGHT: Relacorilant Plus Nab-Paclitaxel Improves Outcomes in Platinum-Resistant Ovarian CancerPublished: June 1st 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Sotatercept Indication for PAH
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5
